{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:34:00Z","timestamp":1793414040933,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32-CA009314"],"award-info":[{"award-number":["T32-CA009314"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA098252"],"award-info":[{"award-number":["P50CA098252"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA06973"],"award-info":[{"award-number":["P30CA06973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13058-018-1061-4","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T13:40:46Z","timestamp":1542116446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Cody","family":"Ramin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty J.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B. S.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiaila M.","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna C.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Petry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0582-8005","authenticated-orcid":false,"given":"Kala","family":"Visvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","volume":"34","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34:611\u201335.","journal-title":"J Clin Oncol"},{"key":"1061_CR2","volume-title":"Bone health and osteoporosis: a report of the Surgeon General","author":"Office of the Surgeon General","year":"2004","unstructured":"Office of the Surgeon General. Bone health and osteoporosis: a report of the Surgeon General. Rockville: U.S. Department of Health and Human Services; 2004."},{"issue":"Suppl 3","key":"1061_CR3","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25(Suppl 3):iii124\u201337.","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"1061_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","volume":"11","author":"JR Gralow","year":"2013","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, et al. NCCN Task Force Report: bone health in cancer care. J Natl Compr Cancer Netw. 2013;11(Suppl 3):S1\u201350.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29:2520\u20136.","journal-title":"J Bone Miner Res"},{"key":"1061_CR6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"154","author":"U.S. Preventive Services Task Force","year":"2011","unstructured":"U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;154:356\u201364.","journal-title":"Ann Intern Med"},{"key":"1061_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11154-010-9154-0","volume":"11","author":"G Karaguzel","year":"2010","unstructured":"Karaguzel G, Holick MF. Diagnosis and treatment of osteopenia. Rev Endocr Metab Disord. 2010;11:237\u201351.","journal-title":"Rev Endocr Metab Disord"},{"key":"1061_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/cncr.21335","volume":"104","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer. 2005;104:1520\u201330.","journal-title":"Cancer"},{"key":"1061_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-014-2928-4","volume":"145","author":"DA Hill","year":"2014","unstructured":"Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, et al. Long-term risk of medical conditions associated with breast cancer treatment. Breast Cancer Res Treat. 2014;145:233\u201343.","journal-title":"Breast Cancer Res Treat"},{"key":"1061_CR10","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1038\/bjc.2011.420","volume":"105 Suppl 1","author":"NF Khan","year":"2011","unstructured":"Khan NF, Mant D, Carpenter L, Forman D, Rose PW. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Br J Cancer. 2011;105 Suppl 1:S29\u201337.","journal-title":"Br J Cancer"},{"key":"1061_CR11","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1158\/1055-9965.EPI-15-0212","volume":"24","author":"AL Gross","year":"2015","unstructured":"Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RBS, Visvanathan K. Weight change in breast cancer survivors compared to cancer-free women: a prospective study in women at familial risk of breast cancer. Cancer Epidemiol Biomark Prev. 2015;24:1262\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1061_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852\u20136.","journal-title":"N Engl J Med"},{"key":"1061_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78\u201384.","journal-title":"J Clin Oncol"},{"key":"1061_CR14","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"\u00c1 Sverrisd\u00f3ttir","year":"2004","unstructured":"Sverrisd\u00f3ttir \u00c1, Fornander T, Jacobsson H, Schoultz EV, Rutqvist LE. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22:3694\u20139.","journal-title":"J Clin Oncol"},{"key":"1061_CR15","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/annonc\/mdr448","volume":"23","author":"K Zaman","year":"2012","unstructured":"Zaman K, Th\u00fcrlimann B, Huober J, Sch\u00f6nenberger A, Pagani O, L\u00fcthi J, Simcock M, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study. Ann Oncol. 2012;23:1474\u201381.","journal-title":"Ann Oncol"},{"key":"1061_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119\u201327.","journal-title":"Lancet Oncol"},{"key":"1061_CR17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135\u201341.","journal-title":"Lancet Oncol"},{"key":"1061_CR18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1359\/jbmr.060508","volume":"21","author":"R Eastell","year":"2006","unstructured":"Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21:1215\u201323.","journal-title":"J Bone Miner Res"},{"key":"1061_CR19","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","volume":"23","author":"PE L\u00f8nning","year":"2005","unstructured":"L\u00f8nning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 Years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126\u201337.","journal-title":"J Clin Oncol"},{"key":"1061_CR20","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"EA Perez","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629\u201335.","journal-title":"J Clin Oncol"},{"key":"1061_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00198-008-0721-0","volume":"20","author":"Z Chen","year":"2009","unstructured":"Chen Z, Maricic M, Aragaki AK, Mouton C, Arendell L, Lopez AM, et al. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women\u2019s Health Initiative. Osteoporos Int. 2009;20:527\u201336.","journal-title":"Osteoporos Int"},{"key":"1061_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, et al. Fracture risk among breast cancer survivors: results from the women\u2019s health initiative observational study. Arch Intern Med. 2005;165:552\u20138.","journal-title":"Arch Intern Med"},{"key":"1061_CR23","doi-asserted-by":"publisher","first-page":"e75109","DOI":"10.1371\/journal.pone.0075109","volume":"8","author":"CH Tsa","year":"2013","unstructured":"Tsa CH, Muo CH, Tzeng HE, Tang CH, Hsu HC, Sung FC. Fracture in asian women with breast cancer occurs at younger age. PLoS One. 2013;8:e75109.","journal-title":"PLoS One"},{"key":"1061_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S1047-2797(03)00056-5","volume":"13","author":"EB Lamont","year":"2003","unstructured":"Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol. 2003;13:698\u2013703.","journal-title":"Ann Epidemiol"},{"key":"1061_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/jgs.12269","volume":"61","author":"PA Pawloski","year":"2013","unstructured":"Pawloski PA, Geiger AM, Haque R, Kamineni A, Fouayzi H, Ogarek J, et al. Fracture risk in older, long-term survivors of early-stage breast cancer. J Am Geriatr Soc. 2013;61:888\u201395.","journal-title":"J Am Geriatr Soc"},{"key":"1061_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1759720X11430858","volume":"4","author":"O Demontiero","year":"2012","unstructured":"Demontiero O, Vidal C, Duque G. Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4:61\u201376.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1061_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.maturitas.2012.08.009","volume":"73","author":"P Taxel","year":"2012","unstructured":"Taxel P, Choksi P, Van Poznak C. The management of osteoporosis in breast cancer survivors. Maturitas. 2012;73:275\u20139.","journal-title":"Maturitas"},{"key":"1061_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(11)70389-8","volume":"13","author":"AM Cheung","year":"2012","unstructured":"Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 2012;13:275\u201384.","journal-title":"Lancet Oncol"},{"key":"1061_CR29","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S1470-2045(14)71035-6","volume":"15","author":"I Sestak","year":"2014","unstructured":"Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2014;15:1460\u20138.","journal-title":"Lancet Oncol"},{"key":"1061_CR30","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.1994.12.5.992","volume":"12","author":"B Kristensen","year":"1994","unstructured":"Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transb\u00f8l I, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994;12:992\u20137.","journal-title":"J Clin Oncol"},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","volume":"24","author":"L Vehmanen","year":"2006","unstructured":"Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24:675\u201380.","journal-title":"J Clin Oncol"},{"key":"1061_CR32","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19:3306\u201311.","journal-title":"J Clin Oncol"},{"key":"1061_CR33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4065\/mcp.2010.0636","volume":"86","author":"CJD Pitts","year":"2011","unstructured":"Pitts CJD, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc. 2011;86:338\u201343.","journal-title":"Mayo Clin Proc"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-018-1061-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T12:56:58Z","timestamp":1589547418000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-018-1061-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1186\/s13058-018-1061-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"14 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained for all subjects, and institutional review board approval was obtained from the Institutional Review Board of Johns Hopkins University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"134"}}